Hypothesis: Abdominal wall tumors, though clinically similar, have varying
degrees of biological behavior.
Design: Retrospective review of prospective databases.
Setting: Memorial Sloan-Kettering Cancer Center.
Patients: Eighty-five patients with abdominal wall soft tissue tumors.
Main Outcome Measures: Primary endpoints included time to first local recur
rence, distant metastases, and disease-related mortality. Survival analysis
was performed by Kaplan-Meier method, and comparisons were made by log-ran
k analysis.
Results: Thirty-nine desmoids, 32 soft tissue sarcomas (STS), and 14 dermat
ofibrosarcoma protuberans (DFSP) underwent surgery directed at achieving ma
rgin-negative resection. Unlike DFSP, most STS (77%) and desmoids(87%) were
deep lesions requiring full-thickness abdominal wall resection and mesh re
construction. Median follow-up time was 53 months, 101 months, and 31 month
s, with 5-year local recurrence-free survival al rates of 97%, 100%, and 75
%, for desmoids, DFSP, and STS, respectively. Desmoid tumors resected with
positive microscopic margins had higher local failure rates (68% [positive
margin] vs 100% [negative margin] 5-yr local recurrence-free survival, P<.0
5). For STS, high grade, deep location, and size at or above 5 cm were adve
rse prognostic factors for disease-specific and distant recurrence-free sur
vival (P<.05); patients experiencing local recurrence was associated with d
ecreased 5-year relapse-free survival rates (87% [primary] vs 50% [local re
currence], P<.05). Characteristically, no DFSP or desmoid developed distant
metastases. Soft tissue sarcomas had significantly lower relapse-free surv
ival rates than DFSP or desmoids (P<.05).
Conclusion: Abdominal wall tumors demonstrate a broad spectrum of biologica
l behavior. Desmoids and DFSP are a local problem. High grade, size at or a
bove 5 cm, and deep location predict distant failure and tumor-related mort
ality for patients with STS. Complete surgical resection is the recommended
treatment approach to achieve local control. Stratification by prognostic
factors will facilitate selection of patients with STS for adjuvant systemi
c therapies.